We've found
6,916 Ovarian Cancer
clinical trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
International Ovarian Tumour Analysis (IOTA) Phase 5
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Ovarian Neoplasms Clinical Trial
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Ovarian Neoplasms Clinical Trial
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
The Women Choosing Surgical Prevention (WISP) Trial
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
The Women Choosing Surgical Prevention (WISP) Trial
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
6,916 Ovarian Cancer
clinical trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
International Ovarian Tumour Analysis (IOTA) Phase 5
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Ovarian Neoplasms Clinical Trial
Updated: 12/31/1969
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Ovarian Neoplasms Clinical Trial
Updated: 12/31/1969
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
Updated: 12/31/1969
The Women Choosing Surgical Prevention (WISP) Trial
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hereditary Breast and Ovarian Cancer Syndrome Clinical Trial
Updated: 12/31/1969
The Women Choosing Surgical Prevention (WISP) Trial
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Updated: 12/31/1969
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Updated: 12/31/1969
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Epithelial Ovarian Cancer Clinical Trial
Updated: 12/31/1969
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials